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Leptomycin Bn (PLTP), one of the key lipid transfer proteins in plasma and cerebrospinal ﬂuid,
is nearly ubiquitously expressed in cells and tissues. Functions of secreted PLTP have been extensively
studied. However, very little is known about potential intracellular PLTP functions. In the current study, we
provide evidence for PLTP localization in the nucleus of cells that constitutively express PLTP (human
neuroblastoma cells, SK-N-SH; and human cortical neurons, HCN2) and in cells transfected with human PLTP
(Chinese hamster ovary and baby hamster kidney cells). Furthermore, we have shown that incubation of
these cells with leptomycin B (LMB), a speciﬁc inhibitor of nuclear export mediated by chromosome region
maintenance 1 (CRM1), leads to intranuclear accumulation of PLTP, suggesting that PLTP nuclear export is
CRM1-dependent. We also provide evidence for entry of secreted PLTP into the cell and its translocation to
the nucleus, and show that intranuclear PLTP is active in phospholipid transfer. These ﬁndings suggest that
PLTP is involved in novel intracellular functions.
© 2009 Elsevier B.V. All rights reserved.1. IntroductionPhospholipid transfer protein (PLTP) is a versatile transfer protein
with predicted protein molecular mass of approximately 55 kDa with
signal peptide, or 53 kDa without [1]. Posttranslational modiﬁcations,
such as N-glycosylation, account for the difference between the
predicted molecular mass, 53 kDa, and observedmass of 81 kDa of the
secreted protein [1]. Secreted PLTP is bound to lipoprotein particles,
and associates with apolipoprotein A-I (apoA-I) and E (apoE), and
with lipoproteins containing other apolipoproteins [2,3]. PLTP func-
tions have been associated with the metabolism of lipoproteins,
particularly high-density lipoproteins (HDL) (reviewed in [4]).
PLTP has been shown to modulate phospholipid and cholesterol
transfer between lipoproteins, as well as between lipoproteins
and cells [5–7]. PLTP also transfers apolipoprotein E (apoE), α-
tocopherol and other molecules such as cerebrosides and diacylgly-
cerides [7–11].
PLTP is expressed by nearly all types of cells and tissues, with wide
variation in expression patterns ([5,12] and unpublished data). For
example, neighboring neurons in Cornu Amonis (CA) layers 1 and 2 in
human hippocampus differ signiﬁcantly in PLTP expression [12].
Interestingly, neurons in the CA1 layer, which express signiﬁcantly
lower levels of PLTP than other hippocampal neurons, are particularly
sensitive to oxidative stress [12,13], and PLTP is one of the key1 206 685 3279.
, Seattle, WA 98119, USA.
l rights reserved.molecules for maintenance of the brain anti-oxidative properties
through regulation of tissue levels of α-tocopherol [11]. These
ﬁndings, along with nearly ubiquitous, yet differential expression of
PLTP in other cells and tissues suggest that PLTP has physiological roles
other than purely extracellular functions related to lipoprotein
metabolism. Although the role of PLTP as a secretory protein has
been extensively studied, nothing is known about the possible
intracellular functions of this protein.
In our immunohistochemical studies of the human brain [12], we
noticed intranuclear staining in neuronal cells using several different
antibodies against PLTP (unpublished data). We tested these initial
observations in order to establish whether PLTP is indeed present in
the nucleus. In this study we provide evidence for PLTP presence and
activity in the nuclear compartment and discuss motifs that could be
involved in PLTP nuclear import and export, implying that PLTP has
novel intracellular functions beyond that of extracellular lipid
transport.2. Materials and methods
2.1. Materials
Dulbecco modiﬁed cell culture media (DMEM) were purchased
from Lonza (Walkersville, MD). Chinese hamster ovary cells prepared
for Flp-In vectors, Flp-In vectors and specialized growth media were
purchased from Invitrogen (Carlsbad, CA). Fetal calf serum was
obtained from HyClone (Logan, UT). Mutagenesis kits were purchased
from Qiagen (Valencia, CA). Leptomycin B (LMB), bovine skin collagen,
Triton X-100 and antibodies against lamin A were purchased from
Fig. 1. PLTP is present in nuclear protein extracts of SK-N-SH neuroblastoma and human
cortical neurons, HCN2 cells, and its nuclear export is chromosome region maintenance
1 (CRM1) dependent. (A) Isolated SK-N-SH nuclear proteins from three different
samples were resolved using SDS-PAGE, and visualized usingWestern blot analysis with
monoclonal anti-PLTP antibody. (B) PLTP Western blot analysis of nuclear proteins
isolated from HCN2 cells incubated without (−) or with (+) 10 ng/ml LMB, a speciﬁc
inhibitor of nuclear export mediated by CRM1, for 24 h under serum-free conditions.
PLTP was identiﬁed using monoclonal anti-PLTP antibody. Loading control was
evaluated using anti-TATA binding protein (TBP). Secondary antibody controls were
negative (not shown).
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other cell culture plastic-ware were purchased from VWR (West
Chester, PA). Methanol-free formaldehyde (16%) was purchased from
Polysciences (Warrington, PA). Monoclonal antibody against PLTP
was produced at the Northwest Lipid Research Laboratory, in
collaboration with Dr. Marcovina [12]. Secondary antibodies for
Western blotting were purchased from eBioscience (San Diego, CA).
Antibodies against TATA binding protein (TBP) for Western loading
control were purchased from Abcam (Cambridge, MA). Biotinylated
secondary antibodies (horse anti-mouse), Vectastain ELITE ABC,
NovaRED and DAB kits, horse serum, hematoxylin, AquaMount and
VectaShield mounting media were purchased from Vector Labora-
tories (Burlingame, CA). Fluorescently labeled secondary antibodies,
chicken anti-mouse AlexaFluor 488 and goat anti-rabbit AlexaFluor
594 antibodies, and Image-iT FX signal enhancer were from
Molecular Probes/Invitrogen (Eugene, OR). PLTP tagged with
enhanced green ﬂuorescent protein (PLTP-EGFP) and mock vectors
were a kind gift from Dr. Vesa Olkkonen, National Public Health
Institute, Helsinki, Finland [14]. Cytoplasmic and nuclear proteins
were isolated using NE-PER kit with addition of protease inhibitor
cocktail, Halt (Pierce, Rockford, IL).
2.2. Cell culture
Experiments were conducted in human neuroblastoma cells (SK-
N-SH), human cortical neurons (HCN2; ATCC CRL-10743), Chinese
hamster ovary (CHO) and baby hamster kidney (BHK) cells. Cells were
incubated in 5% CO2, at 37 °C, supplemented with 5% (SK-N-SH), 10%
(CHO and BHK) or 15% (HCN2) serum in growth media. For standard
immunocytochemistry and ﬂuorescent live-cell imaging cells were
plated in 8-chamber slides, while cells prepared for confocal
microscopy were grown on collagen-treated coverslips in six-well
plates. Cells were incubated without or with 10 ng/ml of LMB for up to
24 h. All experiments were performed in serum-free media, thus
eliminating potential external source of PLTP, conducted in triplicate,
and replicated multiple times.
2.3. PLTP mutagenesis
Site-directed mutagenesis was conducted using wild-type (WT)
PLTP cDNA [1] as a template, using QuickChange site-directed
mutagenesis kit (Stratagene) according to the manufacturer's instruc-
tions. Site-directed in vitro mutagenesis was accomplished by
hybridizing a plasmid containing the PLTP insert (human PLTP C-his
tag/pcDNA5/FRT) to oligonucleotides which are complementary to the
target template except for a region of mismatch near the center,
containing the desired serine-to-alanine mutations. We mutated the
following residues in PLTP: S49A, S79A, S102A, and S128A within the
putative N-glycosylationmotifs (N/X/S-T; numbering based onmature
protein without signal peptide). All created cDNA were veriﬁed by
digestion and sequencing prior to transfection.
2.4. PLTP expression
Recombinant PLTP (rPLTP) constructs containing His tag were
transfected into CHO Flp-In-Ready cells (Invitrogen) using Lipofecta-
mine 2000, and clones were selected using Hygromycin B (0.6 mg/ml;
Invitrogen). PLTP-EGFP constructs were transfected into BHK cells
using Lipofectamine 2000, and positive clones were selected using
G418 (1 mg/ml; Invitrogen). Highest expressing clones for PLTP-EGFP
were selected by measurement of ﬂuorescence (excitation/emission
488/535 nm), and all PLTP clones (wild-type His-tagged and PLTP-
EGFP, as well as mutant PLTP) were conﬁrmed by Western blot
analysis using PLTP-speciﬁc monoclonal antibodies, and by measure-
ment of PLTP phospholipid transfer activity in an in vitro assay [15].2.5. Immunocytochemistry
Following incubation, cells prepared for standard, chromogenic ICC
were ﬁxed with 95% ethanol for 10 min, washed and incubated for
30 min with 3% hydrogen peroxide to reduce endogenous peroxidase.
Slides were blocked with horse serum for 20 min, and incubated with
mouse anti-PLTP antibody (20 μg/ml) overnight at 4 °C, followed by
biotinylated horse anti-mouse antibody (5 μg/ml) for 30 min. The
signal was ampliﬁed using Vectastain ELITE ABC reagents for 30 min,
and stained using DAB or NovaRED kits. The slides were counter-
stained with hematoxylin, coverslipped and observed under Olympus
microscope. Digital images were created using Nikon E990 digital
camera. Cells prepared for confocal microscopy were grown on
coverslips, incubated without or with 10 ng/ml LMB for up to 24 h,
ﬁxed using 3.7% formaldehyde for 15min, and incubatedwith primary
antibodies against PLTP (mouse; 20 μg/ml) and Lamin A (rabbit; 2.5 μg/
ml), as a nuclear marker, at 4 °C overnight. Alexa Fluor secondary
antibodies (chicken anti-mouse Alexa Fluor 488, 5 μg/ml; and goat
anti-rabbit Alexa Fluor 594, 3 μg/ml) for 45 min, rinsed with PBS and
mounted using VectaShield HardSet mounting medium. The slides
were observed under confocal Zeiss LSM 510 Meta microscope, using
water-immersion objective, and recorded using Zeiss LSM 510 soft-
ware, version 4.1 SP1.
2.6. Live cell imaging
Live cells transfected with PLTP-EGFP and grown in 8-chamber
slides in phenol red-free media, incubated without or with LMB
(10 ng/ml), were observed under Zeiss Axiovert inverted ﬂuorescent
microscope, using QColor 3 digital camera and QCapture Pro software.
2.7. PLTP re-entry experiment
Phenol red-free media from control BHK cells and cells transfected
with PLTP-EGFPwere collected after a 24-hour incubation, centrifuged
to remove cells, concentrated using 30 kDa cut-off Amicon Ultra-4
centrifugal ﬁlter device, and added to control BHK cells incubatedwith
vehicle (70% methanol) or 10 ng/ml LMB for 24 h. Following
Fig. 2. PLTP Western blot analysis of nuclear proteins from CHO cells transfected with
the wild-type PLTP (lanes 1 and 3) or PLTP mutant for four glycosylation sites (lanes 2
and 4), incubated without (lanes 1 and 2), or with leptomycin B (LMB; lanes 3 and 4).
PLTP was identiﬁed using monoclonal anti-PLTP antibody. Loading control was
evaluated using anti-TATA binding protein (TBP). Secondary antibody controls were
negative (not shown).
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confocal microscope.
2.8. Western blot
Plated cells were incubated in the presence or absence of LMB from
1 to 24 h. Following incubation, cells were washed, scraped and
cytoplasmic and nuclear extract proteins were isolated using NE-PER
kit (Pierce) following the manufacturer's instructions. Brieﬂy, cells
were lysed using CERI buffer containing protease inhibitor cocktailFig. 3. PLTP immunocytochemistry in neuronal cells. SK-N-SH cells incubated without (a) o
PLTP, and visualized using DAB (brown) and counterstained with hematoxylin (blue). Human
are shown for comparison. Micrographs were obtained using Olympus microscope and Nik(Halt protease inhibitor cocktail, Pierce). Following cell lysis, CERII
buffer was added, and cells were incubated, vortexed and centrifuged
at 16,000 ×g at 4 °C. Cytoplasmic extract was separated and stored at
−80 °C until use. Nuclear pellet was resuspended in NER buffer
containing protease inhibitor cocktail. Lysed nuclei were subjected to
centrifugation, and supernatant containing nuclear extract was stored
at −80 °C until use. Equal amounts of nuclear proteins were separated
by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) on 4–12% Criterion gel (Bio-Rad, Hercules, CA), transferred to
nitrocellulose membrane using semi-dry transfer system (BioRad),
and subjected to Western blot analysis using monoclonal anti-PLTP
antibody (1 μg/ml, overnight incubation at 4 °C), and anti-mouse
secondary antibody that reacts exclusively with non-denatured
immunoglobulin, thus eliminating false positive results (TrueBlot,
eBioscience, San Diego, CA; 0.2 μg/ml, 2 h incubation at room
temperature). Loading control was assessed using anti-TBP (Abcam;
0.08 μg/ml). Positive bands were visualized using West Femto
SuperSignal kit (Pierce). Membranes were digitally scanned using
Kodak CF400 Gel Imager.
2.9. Phospholipid transfer activity assay
PLTP-mediated phospholipid transfer activity was assessed using
PLTP phospholipid transfer activity assay [15]. Nuclear proteins were
assayed for the ability to transfer C14-labeled phospholipid from
donor liposome particles to the acceptor particles (plasma HDL
without measurable PLTP activity). All values were adjusted for the
background transfer, and PLTP activity was calculated as percent of
phospholipid transfer per nanogram of total nuclear protein per hour
(%/ng/h). PLTP-mediated phospholipid transfer activity was conﬁrmed
using anti-PLTP antibody inhibition. Nuclear extracts were incubatedr with (b) leptomycin B (LMB) for 24 h were stained with monoclonal antibody against
cortical neurons (HCN2 cells) incubated without (c) or with 10 ng/ml LMB for 24 h (d)
on E990 digital camera.
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the minimal concentration that elicited complete inhibition of PLTP
activity in the control plasma sample. Samples were then centrifuged
for 20 min at low speed at 4 °C. The supernatant was evaluated for
phospholipid transfer activity. Control chicken IgG was used as
negative control, and assay performance was evaluated using a
plasma sample with known PLTP activity inhibition under identical
conditions.
2.10. Computer analyses
Putative nuclear export motifs in the PLTP sequence were
evaluated using online Nuclear Export Server (NetNES 1.1; http://
www.cbs.dtu.dk/services/NetNES/), and nuclear import motifs were
assessed using an online tool (http://cubic.bioc.columbia.edu/cgi/var/
nair/resonline.pl). Following these analyses, PLTP protein sequence
was further evaluated for nuclear export and nuclear import
sequences based on the published consensus sequences [17–21].
2.11. Statistical analyses
Statistical analyses were performed using Statistica for Windows,
StatSoft, Inc., 2000 (Tulsa, OK). P-valuesb0.05 were considered
statistically signiﬁcant.
3. Results
To establish whether or not PLTP is present in the nuclei of
neurons, we isolated nuclear proteins from SK-N-SH neuroblastoma
cells, and analyzed them by Western blot. The analysis suggested that
PLTP is indeed present in the nuclei (Fig. 1A). Similar results wereFig. 4. Confocal microscopy of nuclear PLTP in SK-N-SH cells. SK-N-SH cells incubated withou
(green; a and d) and Lamin A, a nuclear marker (red; b and e); merged ﬁles (c and f). Secondar
Zeiss LSM 510 Meta microscope, using a water-immersion objective.obtained using a nuclear extract isolated from human cortical neurons
(HCN2; Fig. 1B).
To evaluatewhether PLTP accumulates in nuclei due to inhibition of
the chromosome region maintenance 1 (CRM1) protein, the main
nuclear export protein, we incubated neuronal cells with leptomycin B
(LMB), a speciﬁc inhibitor of CRM1 [22–24]. HCN2 cells were incubated
with LMB, and isolated nuclear proteins were evaluated by Western
blot analyses (Fig. 1B). Similar results were obtained using neuro-
blastoma (SK-N-SH) cells (not shown). Additionally, we evaluated how
glycosylation affects nuclear accumulation of PLTP. Removal of
carbohydrate from four N-glycosylation sites of PLTP, using site-
directed mutagenesis, increased the amount of PLTP in the nuclei of
transfected CHO cells, and its retention in the presence of LMB (Fig. 2).
We also performed immunocytochemistry on cells incubated with
orwithout LMB, usingmonoclonal antibody against PLTP. Our analyses
conﬁrmed that incubation of SK-N-SH and HCN2 cells with LMB leads
to accumulation of PLTP in the nuclei (Figs. 3 and 4). To conﬁrm that
accumulated protein is indeed PLTP, we incubated mock-transfected
and PLTP-EGFP transfected BHK cells with LMB. One hour after the
addition of LMB, we observed live cells under the ﬂuorescent
microscope to evaluate localization of PLTP-EGFP (Fig. 5a). At the
end of the experiment, ﬁxed cells transfected with PLTP-EGFP were
also observed under confocal microscope to conﬁrm intranuclear
localization of PLTP-EGFP (Fig. 5b–h). Both ﬂuorescent and confocal
microscopy conﬁrmed that PLTP is present in the nuclei of the
transfected cells, and that it accumulates in nuclei of cells incubated
with LMB.
In order to establish whether secreted PLTP can enter the cell and
nucleus, conditioned media from control BHK cells and media of BHK
cells transfected with PLTP-EGFPwere incubated with the control BHK
cells for 24 h in the presence or absence of LMB, and observed undert (a–c) and with LMB (d–f) for 24 h were stained with monoclonal antibody against PLTP
y antibody controls were negative (not shown). The slides were observed under confocal
Fig. 5. EGFP-tagged PLTP accumulates in the nuclei of BHK cells incubated with leptomycin B (LMB). Image of live PLTP-EGFP transfected (a) BHK cells incubated with leptomycin B,
viewed under inverted ﬂuorescent microscope after 1 h of incubation with LMB, and representative serial confocal microscopy images (Z-stack) of formaldehyde-ﬁxed PLTP-EGFP
transfected BHK cells following 24 h incubation with LMB (b–h).
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conditioned media without LMB showed sparse positive intracellular
ﬂuorescence, with approximately 1% of cells reaching ﬂuorescence
threshold necessary for observation (not shown). Cells incubated with
PLTP-EGFP containing conditioned media with addition of LMB
showed much higher percentage of clearly positive cells, with
majority of cells containing faint ﬂuorescence, and approximately
20% of cells reaching medium or high intracellular ﬂuorescence levels
(Fig. 6). Positive cells incubated with LMB showed clear accumulation
of ﬂuorescence in the nuclei. Control cells, incubated with conditioned
media from non-transfected BHK cells in the presence or absence of
LMB were negative (not shown).
To establishwhether nuclear PLTP is active inphospholipid transfer,
we performed an in vitro phospholipid transfer assay using nuclearextract from HCN2 cells. Intranuclear PLTP was active in phospholipid
transfer and PLTP-mediated phospholipid transfer activity was signi-
ﬁcantly increased in cells incubated with LMB (control 0.36±0.05%
transfer/ng nuclear protein/h vs. LMB 1.72±0.43%/ng/h). Incubation
with speciﬁc chicken polyclonal anti-PLTP antibody signiﬁcantly
reducedmeasured intranuclear phospholipid transfer activity (control
with anti-PLTP antibody 0.11±0.05%/ng/h, and LMB with anti-PLTP
antibody 0.16±0.06%/ng/h; Fig. 7).
We also conducted computer analysis of the PLTP protein sequence
for the presence of known nuclear motifs involved in nuclear import
and export. The classical nuclear localization signal (NLS) contains
basic amino-acids (R = arginine, K = lysine, and H = histidine) in a
monopartite sequence [K(K/R)XK(K/R)], which typically requires the
presence of lysine residue at the ﬁrst position, or in a bipartite
Fig. 6. PLTP-EGFP re-enters the cells and translocates to the nuclei. Non-transfected BHK
cells were incubated for 24 h with concentrated conditioned media from cells
expressing PLTP-EGFP without (not shown) and with 10 ng/ml leptomycin B (a and
b). Control cells incubated with media from non-transfected BHK cells, without or with
LMB, were negative (not shown).
Fig. 7. Intranuclear PLTP-mediated phospholipid transfer activity in HCN2 cells. Nuclear ext
analyzed for PLTP-mediated phospholipid transfer activity before and after incubation
phospholipid from liposome to HDL particles was measured in vitro. Activity in phospholipi
acceptor per nanogram of total nuclear protein per hour (%/ng/h).
Table 1
Putative nuclear localization (NLS) and export signal (NES) motif candidates in PLTP
molecule (numbering is based on PLTP protein sequence containing signal peptide)
PLTP sequence Putative NLS motif/region
a) 100–104 RFRRQ
b) 372–400 RLSAKMALRGKALRTQLDLRRFRIYSNH
c) 487–489 TPS
PLTP sequence Putative NES motif
1) 3–12 LFGALFLALL
2) 42–51 LEGCLETITI
3) 68–75 VKVTELQL
4) 88–99 LMLQITNASLGL
5) 123–131 VSIRTGLEL
6) 164–180 VYDFLSTFITSGMRFLL
7) 288–302 LLLVGDKVPHDLDML
8) 311–327 IVLLSPAVIDSPLKLEL
9) 344–355 ISVTASVTIALV
10) 401–419 LESLALIPLQAPLKTMLQI
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by 10–12 amino-acid linker region [17–20]. Using an online tool for
search of the consensus nuclear localization sequences (see Materials
and methods), we could not establish that PLTP contains a consensus
sequence for nuclear import, either the canonical or the bi-partite
sequence. This ﬁnding is not unusual, as nuclear import sequences are
more heterogeneous, although most of them require presence of a
cluster of basic amino-acids. Two regions fulﬁlling this later require-
ment were identiﬁed in PLTP, one in the carboxyl-terminal and one in
the amino-terminal barrel of PLTP (Table 1). In addition, a newly
identiﬁed NLS motif (S/T-P-S/T), which responds to extracellular
stimuli and requires phosphorylation for transfer into the nucleus
[25], is present at the C-terminal of PLTP (Table 1).
Furthermore, we identiﬁed several potential consensus nuclear
export sequence (NES) motifs (consensus sequence: ΦX(2-3)ΦX(2-
3)ΦXΦ where Φ stands for either leucine, L, isoleucine, I, valine, V,
phenylalanine, F, or methionine, M; while X stands for any amino-
acid) [21]. Putative consensus NES sequences are distributed in both
the amino- and carboxyl-terminal portion of the PLTP moleculeracts of HCN2 cells incubated without (control) or with LMB (10 ng/ml) for 24 h were
with chicken polyclonal anti PLTP antibody. Transfer of radioactively-labeled (C14)
d transfer is expressed as percent radioactively labeled phospholipid transferred to the
590 S. Vuletic et al. / Biochimica et Biophysica Acta 1793 (2009) 584–591(Table 1). Further evaluation by the online tool, NetNES 1.1, suggested
that each of the identiﬁed putative NES motifs fulﬁlls the basic
requirements for nuclear export. Functionality of thesemotifs remains
to be established.
4. Discussion
In the current study, we present evidence for PLTP localization in
the nucleus of neuronal cells, as well as in mammalian ovary and
kidney cells transfected with human PLTP. These ﬁndings indicate that
PLTP is present in the nuclei of different cell types, and its export from
the nucleus is CRM1-dependent. We also provide evidence for re-
entry of extracellular PLTP into the cell and translocation into the
nucleus. Furthermore, the assay of PLTP phospholipid transfer activity
before and after incubation with anti-PLTP antibody conﬁrmed that
intranuclear PLTP is active in phospholipid transfer.
The current paradigm for protein localization implies that proteins
destined for secretion are targeted to the endoplasmic reticulum (ER)
by a signal peptide sequence at the beginning of mRNA transcription,
then transferred to Golgi and secreted into extracellular space. It is,
therefore, unclear by which mechanism PLTP enters the nucleus. One
possibility is that the signal peptide coded by Exon 2 in PLTP may be
omitted through alternative splicing, or masked by some other
mechanism. An alternative explanation would be that secreted PLTP
re-enters the cells, escapes the endocytic pathway and enters the
nucleus. This type of nuclear translocation is rare, but has been
reported. For example, apoE, a molecular partner of PLTP, has been
shown to translocate into the nucleus following entry into cells
through an apoE receptor-dependent mechanism [26]. Furthermore,
apolipoprotein D has been shown to translocate into the nucleus [27].
One potential explanation may be in the fact that PLTP, apoE and apoD
are bound to lipoprotein particles, which could be taken up by the
cells as holoparticles, allowing for intracellular and intranuclear
localization and function. Indeed, a recently published study has
shown that only apoE associated with lipids is capable of nuclear
translocation [26]. These ﬁndings raise an interesting possibility that
not only cytoplasmic, but also extracellular lipids can enter the
nucleus, providing an important signaling mechanism through which
astrocytes, for example, may be affecting neuronal nuclear-based
functions associated with lipids. Our study provides evidence that at
least a portion of secreted PLTP can re-enter the cell, and that PLTP can
translocate to the nucleus upon re-entry. Interestingly, cells incubated
with secreted PLTP-EGFP show variable intracellular ﬂuorescence,
suggesting the possibility that PLTP reuptake is regulated by some
cellular parameter, such as the cell cycle stage.
It is also possible that the current cellular secretory pathway
paradigm is not correct or that some sequencemotif in a target protein
may allow for exit from the secretory pathway and consequently
permit intracellular or intranuclear localization. For example, numer-
ous recent studies suggest involvement of the endoplasmic reticulum
quality control system, ERAD, as a putative mechanism for transfer of
proteins from the ER to cytoplasm and even nucleus [28–33]. ERAD is
typically involved in transfer of misfolded proteins from the ER for
degradation by the ubiquitin system via an ER translocon, sec61.
Recently published studies suggest that this system is also involved in
transfer of secreted proteins to cytoplasmic and nuclear compart-
ments [28–33]. An interesting review by Arnoys andWang lists nearly
eighty well-documented secreted proteins that are localized in the
nucleus [34]. Data from our experiments suggest that PLTP re-entry
into the cell only partially explains PLTP presence in the nucleus, while
additional nuclear PLTP likely comes from the intracellular pool that
did not get secreted. Therefore, it would be important to further
explore putative mechanisms involved in the intracellular and
intranuclear localization of PLTP.
Although it is currently not knownwhat functional roles PLTP may
be playing in the nucleus, there are several likely possibilities.Typically, shuttling of proteins between cytoplasm and nucleus is
important for regulation of cellular functions, such as cell proliferation
and differentiation, and for maintenance of the cellular structural
stability and function. Alterations in nucleocytoplasmic shuttling for
numerous transcription factors have been associated with pathophy-
siological processes involved in development of AD, Parkinson's
disease, amyotrophic lateral sclerosis and Huntington's disease,
among others (reviewed in [35]). Gene expression can be regulated
by factors that modify chromatin and by signaling molecules, as well
as by factors regulating lipid content of the nucleus [35–37].
We have shown that intranuclear PLTP is active in lipid transport,
suggesting that PLTP may be involved in regulation, transport and
distribution of phospholipids and cholesterol in the nucleus. Numer-
ous studies have shown that lipids are an integral part of the nucleus
[38–43]. Lipids are present not only in the nuclear envelope, but also
in the nuclear matrix and chromatin [37,44–45]. Additionally, elegant
experiments by Albi et al. have shown that at least some of the
phospholipids present in chromatin, which represent approximately
10% of the nuclear phospholipids, are transported into the nucleus
from the cytoplasm [46], while others may be synthesized in situ [37].
Although endonuclear lipids were initially considered relevant only
for structural stability of the nucleus, an increasing body of evidence
suggests their functional contribution to other nuclear processes. For
example, endonuclear lipids have been associated with endonuclear
lipid second messenger signaling, thus affecting processes involved in
cell proliferation, differentiation and apoptosis [36,37]. Furthermore,
nuclear composition of lipids is cell type and cell cycle phase speciﬁc
[37]. Despite the overwhelming evidence of lipid transfer of
cholesterol and phospholipids to and from the nucleus, the processes
and components of this lipid transfer are currently unknown [37].
Given the PLTP's wide afﬁnity for free cholesterol and different classes
of phospholipids, it is reasonable to speculate that PLTP may be
involved in this process.
PLTP is also necessary for transfer of α-tocopherol to cells and
tissues [11]. Guarnieri et al. have shown that α-tocopherol is present
in the nuclei, and suggested that α-tocopherol may be involved in the
regulation of RNA synthesis [47]. Further studies conﬁrmed the
importance of α-tocopherol in preservation of RNA structure, and
reduction in nuclear α-tocopherol content had similar effects on
nuclear components as aging [48]. Additionally, intranuclear antiox-
idative potential may be relevant not only in aging, but also in
pathophysiology of various diseases, such as Alzheimer's disease or
cancer. Since PLTP is critical for transfer of α-tocopherol to the cells, it
is possible that it may be also involved in its transfer to the nucleus.
A recent study implicated PLTP as the main component in one of
the nine pathways that regulate survival in breast cancer [49], and
PLTP has been differentially expressed in numerous tumors, including
different types of leukemia ([50–52] and data obtained through data
mining), but the mechanisms through which PLTP may be affecting
these processes are currently unknown. It is possible that intracellular,
and in particular intranuclear PLTP localization and functions are
relevant for these processes, and unraveling the mechanisms control-
ling PLTP intracellular compartmentalizationwould be important. Our
study and its potential implications may be relevant for our under-
standing of the roles of PLTP in numerous human diseases, including
Alzheimer's disease, cardiovascular disease, diabetes and cancer.
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